These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 27161090)

  • 1. Pathological outcomes and agressiveness of low-risk prostate cancer in Northern African men.
    Ammani A; Janane A; Bouzide B; Dehayni Y; Lezrek M; Ghadouane M; Ameur A; Abbar M; Qarro A; Alami M
    Actas Urol Esp; 2016 Nov; 40(9):556-563. PubMed ID: 27161090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
    Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
    Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the aggressiveness of prostate cancer among Korean, Caucasian, and African American men: A retrospective cohort study of radical prostatectomy.
    Jeong IG; Dajani D; Verghese M; Hwang J; Cho YM; Hong JH; Kim CS; Ahn H; Ro JY
    Urol Oncol; 2016 Jan; 34(1):3.e9-14. PubMed ID: 26345648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.
    Jalloh M; Myers F; Cowan JE; Carroll PR; Cooperberg MR
    Eur Urol; 2015 Mar; 67(3):451-7. PubMed ID: 24746973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance.
    Ha YS; Salmasi A; Karellas M; Singer EA; Kim JH; Han M; Partin AW; Kim WJ; Lee DH; Kim IY
    Urology; 2013 Apr; 81(4):831-5. PubMed ID: 23465143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pathological data between prostate biopsy and radical prostatectomy specimen in patients with low to very low risk prostate cancer.
    Lendínez-Cano G; Alonso-Flores J; Beltrán-Aguilar V; Cayuela A; Salazar-Otero S; Bachiller-Burgos J
    Actas Urol Esp; 2015 Oct; 39(8):482-7. PubMed ID: 25895440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.
    Sundi D; Kryvenko ON; Carter HB; Ross AE; Epstein JI; Schaeffer EM
    J Urol; 2014 Jan; 191(1):60-7. PubMed ID: 23770146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance.
    Tosoian JJ; JohnBull E; Trock BJ; Landis P; Epstein JI; Partin AW; Walsh PC; Carter HB
    J Urol; 2013 Oct; 190(4):1218-22. PubMed ID: 23643603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Population-Based Study of Men With Low-Volume Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?
    Schreiber D; Chhabra A; Rineer J; Weedon J; Schwartz D
    Clin Genitourin Cancer; 2015 Aug; 13(4):e259-e264. PubMed ID: 25777681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment.
    Dall'Era MA; Cowan JE; Simko J; Shinohara K; Davies B; Konety BR; Meng MV; Perez N; Greene K; Carroll PR
    BJU Int; 2011 Apr; 107(8):1232-7. PubMed ID: 20804478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Pathological Upgrading and Up Staging among Men with Low Risk Prostate Cancer Varies by Race: Results from the National Cancer Database.
    Maurice MJ; Sundi D; Schaeffer EM; Abouassaly R
    J Urol; 2017 Mar; 197(3 Pt 1):627-631. PubMed ID: 27582435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men.
    Eastham JA; Carver B; Katz J; Kattan MW
    Prostate; 2002 Mar; 50(4):236-40. PubMed ID: 11870801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
    Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
    Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer.
    Eastham JA; Kattan MW
    J Urol; 2000 Jan; 163(1):143-5. PubMed ID: 10604332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
    Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
    World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease.
    Powell IJ; Banerjee M; Novallo M; Sakr W; Grignon D; Wood DP; Pontes JE
    Urology; 2000 Feb; 55(2):246-51. PubMed ID: 10688088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
    Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
    BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparities in Hispanic/Latino and non-Hispanic Black men with low-risk prostate cancer and eligible for active surveillance: a population-based study.
    Katz JE; Chinea FM; Patel VN; Balise RR; Venkatramani V; Gonzalgo ML; Ritch C; Pollack A; Parekh DJ; Punnen S
    Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):533-538. PubMed ID: 29988097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.